Literature DB >> 22150057

Myeloma and second primary cancers.

Ola Landgren, Anish Thomas, Sham Mailankody.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22150057      PMCID： PMC7213755          DOI： 10.1056/NEJMc1111010

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment.

Authors:  A J Swerdlow; J A Barber; G V Hudson; D Cunningham; R K Gupta; B W Hancock; A Horwich; T A Lister; D C Linch
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

Review 2.  Mechanisms of therapy-related carcinogenesis.

Authors:  James M Allan; Lois B Travis
Journal:  Nat Rev Cancer       Date:  2005-12       Impact factor: 60.716

3.  Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma.

Authors:  O Landgren; W Ma; R A Kyle; S V Rajkumar; N Korde; M Albitar
Journal:  Leukemia       Date:  2011-09-16       Impact factor: 11.528

4.  Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS).

Authors:  Sham Mailankody; Ruth M Pfeiffer; Sigurdur Y Kristinsson; Neha Korde; Magnus Bjorkholm; Lynn R Goldin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2011-07-27       Impact factor: 22.113

5.  Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study.

Authors:  Ingemar Turesson; Ramon Velez; Sigurdur Y Kristinsson; Ola Landgren
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544
  5 in total
  18 in total

1.  Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study.

Authors:  Gudbjörg Jonsdottir; Sigrún H Lund; Magnus Björkholm; Ingemar Turesson; Anders Wahlin; Sham Mailankody; Cecilie Blimark; Malin Hultcrantz; Anna Porwit; Ola Landgren; Sigurdur Y Kristinsson
Journal:  Haematologica       Date:  2015-12-17       Impact factor: 9.941

Review 2.  Second malignancies after multiple myeloma: from 1960s to 2010s.

Authors:  Anish Thomas; Sham Mailankody; Neha Korde; Sigurdur Y Kristinsson; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2012-02-06       Impact factor: 22.113

3.  Trends in cause of death among patients with multiple myeloma in Puerto Rico and the United States SEER population, 1987-2013.

Authors:  Maira A Castañeda-Avila; Karen J Ortiz-Ortiz; Carlos R Torres-Cintrón; Brenda M Birmann; Mara M Epstein
Journal:  Int J Cancer       Date:  2019-03-30       Impact factor: 7.396

Review 4.  Metastatic Merkel cell carcinoma in the bone marrow of a patient with plasma cell myeloma and therapy-related myelodysplastic syndrome.

Authors:  Megan Kielt Kressin; Annette S Kim
Journal:  Int J Clin Exp Pathol       Date:  2012-10-20

Review 5.  Update on second primary malignancies in multiple myeloma: a focused review.

Authors:  O Landgren; S Mailankody
Journal:  Leukemia       Date:  2014-01-14       Impact factor: 11.528

6.  The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study.

Authors:  Gudbjörg Jonsdottir; Sigrún H Lund; Magnus Björkholm; Ingemar Turesson; Malin Hultcrantz; Anna Porwit; Yogesh S Jethava; Ola Landgren; Sigurdur Y Kristinsson
Journal:  Blood Adv       Date:  2017-11-22

7.  A case of multiple primary malignancies and investigation of family history.

Authors:  Xiu-Yan Huang; Zi-Li Huang; Jin Huang; Zhi-Gang Wang; Qi Zheng
Journal:  Oncol Lett       Date:  2012-08-29       Impact factor: 2.967

8.  Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma.

Authors:  Kai Song; Brett H Herzog; Minjia Sheng; Jianxin Fu; J Michael McDaniel; Hong Chen; Jia Ruan; Lijun Xia
Journal:  Cancer Res       Date:  2013-10-24       Impact factor: 12.701

9.  Longitudinal bone marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide.

Authors:  Sara A Monaghan; Lijun Dai; Markus Y Mapara; Daniel P Normolle; Susanne M Gollin; Suzanne Lentzsch
Journal:  Leuk Lymphoma       Date:  2013-01-28

10.  Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.

Authors:  Idrees Mian; Denái R Milton; Nina Shah; Yago Nieto; Uday R Popat; Partow Kebriaei; Simrit Parmar; Betul Oran; Jatin J Shah; Elisabet E Manasanch; Robert Z Orlowski; Elizabeth J Shpall; Richard E Champlin; Muzaffar H Qazilbash; Qaiser Bashir
Journal:  Cancer       Date:  2016-09-28       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.